Clinical trial · Interventional
Phase I/II Study of High-Dose Calcitriol Plus Temodar for Patients With Metastatic Melanoma
A Phase I/II Study of High-Dose Calcitriol in Combination With Temozolomide for Patients With Metastatic Melanoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Calcitriol may help temozolomide kill more tumor cells by making them more sensitive to the drug. Calcitriol may also stop the growth of melanoma by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the best dose of calcitriol, the side effects of calcitriol when given together with temozolomide, and to see how well they work in treating patients with metastatic stage IV melanoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Melanoma | Melanoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Calcitriol | Dietary Supplement | — | UNRESOLVED |
| Temozolomide | Drug | Temozolomide | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Cohort 1 - Temozolomide and Calcitriol
- description
- Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days. Calcitriol dose of 0.2 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days.
- interventionNames
- Dietary Supplement: Calcitriol
- Drug: Temozolomide
- type
- EXPERIMENTAL
- label
- Cohort 2 - Temozolomide and Calcitriol
- description
- Temozolomide dose of 150 mg/m2 will be administered orally on days 2-8 and 16-22 every cycle where 1 cycle equals 28 days. Calcitriol dose of 0.3 mcg/kg will be administered orally on days 1 and 15 every cycle where 1 cycle equals 28 days.
- interventionNames
- Dietary Supplement: Calcitriol
- Drug: Temozolomide
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed malignant melanoma * Any primary tumor site * Stage IV disease * CNS metastases allowed * Measurable disease, defined as at least 1 lesion that can be accurately measured in at least 1 dimension as ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan * Must have had at least 1 prior systemic therapy * Negative pregnancy test * Fertile patients must use effective contraception * Patients with no prior systemic therapy are eligible provided they are not candidates for high-dose interleukin-2 * Recovered from all toxic effects of prior therapy * More than 4 weeks since prior and no concurrent radiotherapy, chemotherapy, or immunotherapy * More than 4 weeks since prior and no concurrent radiotherapy, chemotherapy, or immunotherapy * Fertile patients must use effective contraception Exclusion Criteria: * Life expectancy less than 4 months * known HIV positivity * evidence of active infection requiring antibiotic therapy * other malignancy within the past 5 years except surgically resected basal cell or squamous cell skin cancer * significant medical disease which, in the opinion of the investigator, may interfere with study completion * pregnant or nursing * Negative pregnancy test * prior temozolomide or dacarbazine * investigational agent within 4 weeks prior to study entry * concurrent magnesium-containing antacids, digitalis, bile-resin binding drugs, or calcium supplements
References
Publications (0)
Data not yet available